Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes

被引：1

作者：

Nakajima, Hideaki ^{[1
]}

机构：

[1] Yokohama City Univ, Dept Stem Cell & Immune Regulat, Grad Sch Med, Yokohama, Kanagawa, Japan

来源：

INTERNAL MEDICINE | 2021年 / 60卷 / 01期

基金：

日本学术振兴会;

关键词：

myelodysplastic syndromes; MDS; molecular pathogenesis; genome; epigenome; treatment; NEDD8-ACTIVATING ENZYME-INHIBITOR; CONVENTIONAL CARE REGIMENS; OPEN-LABEL; PROGNOSTIC-SIGNIFICANCE; SOMATIC MUTATIONS; COHESIN COMPLEX; SF3B1; MUTATION; SELF-RENEWAL; MUTANT IDH2; TET2; LOSS;

D O I：

10.2169/internalmedicine.4214-19

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Myelodysplastic syndromes (MDS) are clonal hematological disorders arising from hematopoietic stem cells that have accumulated various genetic abnormalities. MDS are heterogeneous in nature but uniformly characterized by chronic and progressive cytopenia from ineffective hematopoiesis, dysplasia in single or multiple lineages, and transformation to acute leukemia in a subset of patients. The genomic landscape revealed by next-generation sequencing has provided a comprehensive picture of the molecular pathways involved in MDS pathogenesis. Recurrent mutational targets in MDS are the genes involved in RNA splicing, DNA methylation, histone modification, transcription, signal transduction, cohesin complex and DNA repair. Sequential acquisition of mutations in these sets of genes serves as a driver for the initiation, clonal evolution and progression of MDS. Based on these findings, novel agents targeting driver mutations of MDS are currently under development and expected to improve the clinical outcome of MDS in the coming decades.

引用

页码：15 / 23

页数：9

共 74 条

[1] A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome [J].

Barlow, Jillian L. ;

Drynan, Lesley F. ;

Hewett, Duncan R. ;

Holmes, Luke R. ;

Lorenzo-Abalde, Silvia ;

Lane, Alison L. ;

Jolin, Helen E. ;

Pannell, Richard ;

Middleton, Angela J. ;

Wong, See Heng ;

Warren, Alan J. ;

Wainscoat, James S. ;

Boultwood, Jacqueline ;

McKenzie, Andrew N. J. .

NATURE MEDICINE, 2010, 16 (01) :59-U93

[2] Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes [J].

Bejar, Rafael ;

Stevenson, Kristen E. ;

Caughey, Bennett A. ;

Abdel-Wahab, Omar ;

Steensma, David P. ;

Galili, Naomi ;

Raza, Azra ;

Kantarjian, Hagop ;

Levine, Ross L. ;

Neuberg, Donna ;

Garcia-Manero, Guillermo ;

Ebert, Benjamin L. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) :3376-3382

[3] Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution [J].

Bernasconi, P ;

Klersy, C ;

Boni, M ;

Cavigliano, PM ;

Calatroni, S ;

Giardini, I ;

Rocca, B ;

Zappatore, R ;

Caresana, M ;

Quarna, J ;

Lazzarino, M ;

Bernasconi, C .

LEUKEMIA, 2005, 19 (08) :1424-1431

[4] Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome [J].

Boultwood, J ;

Fidler, C ;

Strickson, AJ ;

Watkins, F ;

Gama, S ;

Kearney, L ;

Tosi, S ;

Kasprzyk, A ;

Cheng, JF ;

Jaju, RJ ;

Wainscoat, JS .

BLOOD, 2002, 99 (12) :4638-4641

[5] Advances in the 5q- syndrome [J].

Boultwood, Jacqueline ;

Pellagatti, Andrea ;

McKenzie, Andrew N. J. ;

Wainscoat, James S. .

BLOOD, 2010, 116 (26) :5803-5811

[6] Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ [J].

Brownell, James E. ;

Sintchak, Michael D. ;

Gavin, James M. ;

Liao, Hua ;

Bruzzese, Frank J. ;

Bump, Nancy J. ;

Soucy, Teresa A. ;

Milhollen, Michael A. ;

Yang, Xiaofeng ;

Burkhardt, Anne L. ;

Ma, Jingya ;

Loke, Huay-Keng ;

Lingaraj, Trupti ;

Wu, Dongyun ;

Hamman, Kristin B. ;

Spelman, James J. ;

Cullis, Courtney A. ;

Langston, Steven P. ;

Vyskocil, Stepan ;

Sells, Todd B. ;

Mallender, William D. ;

Visiers, Irache ;

Li, Ping ;

Claiborne, Christopher F. ;

Rolfe, Mark ;

Bolen, Joseph B. ;

Dick, Lawrence R. .

MOLECULAR CELL, 2010, 37 (01) :102-111

[7] Dnmt3a is essential for hematopoietic stem cell differentiation [J].

Challen, Grant A. ;

Sun, Deqiang ;

Jeong, Mira ;

Luo, Min ;

Jelinek, Jaroslav ;

Berg, Jonathan S. ;

Bock, Christoph ;

Vasanthakumar, Aparna ;

Gu, Hongcang ;

Xi, Yuanxin ;

Liang, Shoudan ;

Lu, Yue ;

Darlington, Gretchen J. ;

Meissner, Alexander ;

Issa, Jean-Pierre J. ;

Godley, Lucy A. ;

Li, Wei ;

Goodell, Margaret A. .

NATURE GENETICS, 2012, 44 (01) :23-U43

[8] Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level [J].

Chen, Jiahao ;

Kao, Yun-Ruei ;

Sun, Daqian ;

Todorova, Tihomira I. ;

Reynolds, David ;

Narayanagari, Swathi-Rao ;

Montagna, Cristina ;

Will, Britta ;

Verma, Amit ;

Steidl, Ulrich .

NATURE MEDICINE, 2019, 25 (01) :103-+

[9] Cancer-associated IDH1 mutations produce 2-hydroxyglutarate [J].

Dang, Lenny ;

White, David W. ;

Gross, Stefan ;

Bennett, Bryson D. ;

Bittinger, Mark A. ;

Driggers, Edward M. ;

Fantin, Valeria R. ;

Jang, Hyun Gyung ;

Jin, Shengfang ;

Keenan, Marie C. ;

Marks, Kevin M. ;

Prins, Robert M. ;

Ward, Patrick S. ;

Yen, Katharine E. ;

Liau, Linda M. ;

Rabinowitz, Joshua D. ;

Cantley, Lewis C. ;

Thompson, Craig B. ;

Heiden, Matthew G. Vander ;

Su, Shinsan M. .

NATURE, 2009, 462 (7274) :739-U52

[10] Somatic mutations precede myeloid leukemia years before diagnosis [J].

Desai, Pinkal ;

Mencia-Trinchant, Nuria ;

Savenkov, Oleksandr ;

Simon, Michael S. ;

Cheang, Gloria ;

Lee, Sangmin ;

Samuel, Michael ;

Ritchie, Ellen K. ;

Guzman, Monica L. ;

Ballman, Karla V. ;

Roboz, Gail J. ;

Hassane, Duane C. .

NATURE MEDICINE, 2018, 24 (07) :1015-+

← 1 2 3 4 5 6 7 8 →